CMO/CDMO Market to Reach $5.46 Billion by 2035 as Biologics Manufacturing Outsourcing Accelerates

Key Takeaways

• CMO/CDMO market projected to grow at 3.1% CAGR, reaching $5.46 billion by 2035 from $4.02 billion in 2025
• Biologics and biosimilars pipeline expansion driving increased outsourcing demand for specialized manufacturing capabilities
• Pharmaceutical sponsors prioritizing end-to-end regulatory support and faster time-to-market solutions from contract partners

---

CMO/CDMO Market Growth Driven by Biologics Surge

The global Contract Manufacturing Organization (CMO) and Contract Development and Manufacturing Organization (CDMO) market is positioned for steady expansion, with industry analysts projecting growth from USD 4.02 billion in 2025 to USD 5.46 billion by 2035.

Market Drivers Reshape Manufacturing Landscape

The pharmaceutical industry’s increasing reliance on biologics and biosimilars is fundamentally reshaping the contract manufacturing sector. Strong pipeline development in these complex therapeutic areas requires specialized manufacturing expertise that many pharmaceutical companies are choosing to outsource rather than develop in-house.

Regulatory agencies’ support for accelerated approval pathways is creating additional momentum, as sponsors seek partners capable of navigating complex regulatory requirements while maintaining manufacturing flexibility. This trend is particularly pronounced in the European market, where regulatory harmonization efforts are streamlining approval processes.

Technology and Sustainability Drive Partner Selection

Pharmaceutical sponsors are increasingly selective when choosing manufacturing partners, prioritizing organizations that offer comprehensive solutions beyond basic manufacturing services. The shift toward tech-enabled manufacturing platforms reflects the industry’s broader digital transformation, with companies seeking partners who can provide real-time data analytics, process optimization, and supply chain transparency.

Sustainability considerations are also influencing partner selection, as pharmaceutical companies face growing pressure to reduce their environmental footprint throughout the manufacturing process.

Quality and Compliance Remain Paramount

Despite the focus on speed and flexibility, quality systems and data integrity continue to be non-negotiable requirements. The emphasis on compliance reflects lessons learned from recent regulatory actions and the industry’s commitment to maintaining the highest manufacturing standards.

The market’s steady 3.1% compound annual growth rate suggests a maturing industry that balances growth opportunities with operational excellence and regulatory compliance.

---

Frequently Asked Questions

What is driving growth in the CMO/CDMO market?

Growth is primarily driven by increased outsourcing of biologics and biosimilars manufacturing, regulatory support for accelerated approvals, and demand for specialized, tech-enabled manufacturing solutions.

How large will the CMO/CDMO market become by 2035?

The market is projected to reach USD 5.46 billion by 2035, growing from USD 4.02 billion in 2025 at a compound annual growth rate of 3.1%.

What do pharmaceutical companies prioritize when selecting CMO/CDMO partners?

Companies prioritize end-to-end regulatory support, faster time-to-market capabilities, robust quality systems, data integrity, and compliance with regulatory standards.